Q-omics provides the consensus-scored ZNF728 profile across patient tissues and cancer cell-line models. ZNF728 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF728 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, ZNF728 RNA expression shows 20,347 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, KIRC, and PDAC as cancer lineages where ZNF728 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF728 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF728 survival associations across molecular data types. ZNF728 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF728 RNA expression–survival associations across cancer types. High ZNF728 expression shows unfavorable associations in LUSC and UCS, but favorable associations in LUAD, UVM, MESO and ACC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF728 RNA expression.
This table summarizes ZNF728 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF728. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF728 shows lower tumor expression in KIRC, COAD, KICH, LUSC, BLCA and UCEC. The KIRC box plot shows higher ZNF728 RNA expression in normal versus tumor tissue (log2 FC = −1.182, t-test p < 0.001).
This table shows molecular features associated with ZNF728 in patient tissues and cancer cell lines. In patient samples, ZNF728 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF728 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
